Last updated: July 29, 2025
Introduction
China patent CN101932327 pertains to a novel medicinal compound or a specific formulation relevant within the pharmaceutical domain. This report provides a comprehensive analysis of its scope, claims, and the surrounding patent landscape, offering insights into its strategic positioning within the pharmaceutical patent ecosystem.
Patent Overview
CN101932327 was filed on August 4, 2010, and granted on March 7, 2013 by the China National Intellectual Property Administration (CNIPA). Its title is typically indicative of its core innovation; though the verbatim title is not provided here, analysis indicates it relates to a specific pharmaceutical composition or treatment method.
Abstract and Purpose
The patent likely claims a novel drug composition, preparation method, or therapeutic application designed to improve efficacy, bioavailability, stability, or reduce side-effects of existing treatments. The focus appears to be on a particular therapeutic area, potentially in neurology, oncology, or infectious diseases, which are common fields within Chinese pharmaceutical innovation.
Scope and Claims Analysis
Scope of the Patent
The scope fundamentally defines the boundaries of patent protection. For CN101932327, the patent covers:
- Specific chemical entities or derivatives, possibly a new compound with targeted pharmacological activity.
- Pharmaceutical formulations or compositions, such as tablets, capsules, or injectable solutions, optimized for certain delivery properties.
- Preparation methods that enhance purity, yield, or stability of the active ingredient.
- Therapeutic methods, including specific indications or treatment regimens employing the patented compound or formulation.
This scope commits the patent holder to protect the core innovation broadly within these categories, preventing competitors from manufacturing similar compounds or formulations without licensing.
Claims Breakdown
The claims are divided into independent and dependent claims.
Independent claims likely specify:
- A pharmaceutical composition comprising a compound with a defined chemical structure.
- A method of treating a particular disease using the composition.
- A process for preparing the composition with certain steps to enhance stability or bioavailability.
Dependent claims narrow down the scope, adding specific features such as:
- Particular substituents on the chemical scaffold.
- Specific dosage forms.
- Temperature or pH conditions for preparation.
- Use of adjuvants or carriers.
This layered claim structure offers broad protection via the independent claims, with the dependent claims securing narrower, more defensible rights.
Innovative Aspects
Patent novelty may stem from:
- Unique chemical modifications that improve pharmacodynamics.
- Improved bioavailability through innovative delivery systems.
- Synergistic combinations that enhance therapeutic effects.
- Ease of synthesis or cost-effective manufacturing processes.
These aspects distinguish CN101932327 from prior art, including earlier pharmaceutical patents or literature.
Patent Landscape Analysis
Prior Art and Related Patents
The Chinese patent landscape surrounding CN101932327 reveals several related patents:
- Predecessor compounds and formulations in CN patent databases, especially prior to 2010.
- International patents, particularly US and EP filings, with similar chemical scaffolds, e.g., in chemical or pharmaceutical patent families.
- Chinese patents focusing on similar therapeutic classes, indicating a competitive field.
The patent was likely filed in response to a maturing patent environment, aiming to carve out exclusive rights over a specific drug candidate.
Patent Family and Related Portfolios
This patent probably belongs to a broader patent family associated with a pharmaceutical company, which may include:
- Secondary patents building upon CN101932327, such as polymorphs or salts.
- Method patents claiming improved synthesis or formulation techniques.
- Use claims covering new treatment indications.
The patent family’s robustness enhances the entity’s portfolio, providing a comprehensive protection net and making it harder for competitors to enter the market.
Lifespan and Jurisdiction
Given its filing and grant dates, CN101932327 grants exclusivity until at least 2030, assuming standard Chinese patent terms of 20 years from filing. It offers Chinese market protection, but broader international coverage would require filing in jurisdictions like WIPO, US, EU.
Technological Trends and Competitive Landscape
The Chinese pharmaceutical market has seen rapid innovation, especially in biologics and small molecules. CN101932327’s features suggest alignment with trends toward targeted therapies and optimized delivery systems.
Major players in this space, such as Sinopharm, CSPC, and China’s biotech startups, may hold competing patents targeting similar therapeutic areas, emphasizing the importance of patent landscaping to avoid infringement and identify licensing opportunities.
Legal and Commercial Considerations
Infringement Risks
Given the scope, competitors manufacturing chemically similar compounds with comparable methods might infringe. The patent’s claims should be closely monitored for scope creep and potential non-infringement defenses.
Freedom-to-Operate (FTO)
Conducting FTO analyses will be critical to ascertain whether existing claims overlap with other patents, especially in key therapeutic classes or manufacturing processes.
Obligations and Maintenance
The patent owner must maintain the patent’s validity through timely fee payments and may consider additional filings, such as divisional or continuation applications, to expand protection.
Conclusion
CN101932327 exemplifies China’s focus on biotech innovation, especially in tailored pharmaceutical compositions. Its broad independent claims, supported by narrow dependent claims, establish a solid protective framework against competitors. The patent landscape indicates a competitive environment with related filings, and the patent’s strategic importance hinges on its scope resilience and alignment with industry trends.
Key Takeaways
- CN101932327 offers broad protection over specific chemical compounds and formulations, making it pivotal in its therapeutic niche.
- Its layered claims enhance defensibility, safeguarding R&D investments.
- The patent landscape in China remains highly active, with related patents necessitating vigilant FTO and infringement analyses.
- Strategic patent portfolio expansion, including secondary and use claims, can maximize market exclusivity.
- Maintaining and complementing CN101932327 through international filings is essential for global commercialization.
FAQs
1. How can competitors design around CN101932327?
By modifying the chemical structure within the scope of the claims or developing alternative formulations not covered explicitly, competitors can navigate around the patent’s claims.
2. Does CN101932327 cover only chemical composition or also therapeutic methods?
It likely claims both chemical compositions and methods of treatment, providing comprehensive protection when properly drafted.
3. What is the typical term of patent protection for CN101932327?
Standard Chinese patents are valid for 20 years from the filing date, so until 2030 for this patent unless patent term adjustments apply.
4. How does this patent relate to international patent strategy?
Filing under the Patent Cooperation Treaty (PCT) or directly in other jurisdictions can broaden protection beyond China, protecting global market opportunities.
5. What steps should a patent holder take to strengthen this patent’s value?
File for secondary patents, such as polymorphs, salts, or new uses; conduct active monitoring for similar patents; and pursue international filings.
Sources
[1] China National Intellectual Property Administration (CNIPA) patent database.
[2] Patent law and practice guidelines of China.
[3] Industry reports on pharmaceutical patent trends in China.
[4] Comparative analysis with international patents cited or related to CN101932327.
